In the article that accompanies this editorial, Hamanishi et al 7 report a multicenter, randomized, open-label phase III trial (NINJA) that evaluated the safety and efficacy of nivolumab compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback